Breast cancer incidence and hormone therapy use before and after the Women's Health Initiative (WHI) estrogen (E) plus progestin (P) trial by race/ethnicity

被引：0
|
作者：
Chlebowski, Rowan T. [1 ]
Aragaki, Aaron K. [2 ]
Anderson, Garnet L. [2 ]
Prentice, Ross L. [2 ]
机构：
[1] Harbor UCLA Med Ctr, Torrance, CA 90509 USA
[2] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA
来源：
CANCER RESEARCH | 2019年 / 79卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2019-LB-170
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LB-170
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Prior hormone therapy and breast cancer risk in the Women's Health initiative randomized trial of estrogen plus progestin
    Anderson, Garnet L.
    Chlebowski, Rowan T.
    Rossouw, Jacques E.
    Rodabough, Rebecca J.
    McTiernan, Anne
    Margolis, Karen L.
    Aggerwal, Anita
    Curb, J. David
    Hendrix, Susan L.
    Hubbell, F. Allan
    Khandekar, Jamardan
    Lane, Dorothy S.
    Lasser, Norman
    Lopez, Ana Maria
    Potter, JoNell
    Ritenbaugh, Cheryl
    MATURITAS, 2006, 55 (02) : 103 - 115
  • [2] Estrogen/progestin (E+P) therapy and gallbladder outcomes in postmenopausal sal women: The women's health initiative (WHI)
    Cirillo, D
    Wallace, R
    Rodabough, R
    Greenland, P
    LaCroix, A
    Limacher, M
    AMERICAN JOURNAL OF EPIDEMIOLOGY, 2004, 159 (11) : S99 - S99
  • [3] Postmenopausal hormone therapy and body composition - a substudy of the estrogen plus progestin trial of the Women's Health Initiative
    Chen, Z
    Bassford, T
    Green, SB
    Cauley, JA
    Jackson, RD
    LaCroix, AZ
    Leboff, M
    Stefanick, ML
    Margolis, KL
    AMERICAN JOURNAL OF CLINICAL NUTRITION, 2005, 82 (03): : 651 - 656
  • [4] Breast cancer after stopping estrogen plus progestin in postmenopausal women in the women's health initiative.
    Chlebowski, R. T.
    Kuller, L.
    Anderson, G.
    Mason, J. A.
    Schenken, R.
    Rajkovic, A.
    Stefanick, M.
    Sarto, G.
    Ravdin, P.
    Prentice, R.
    CANCER RESEARCH, 2009, 69 (02) : 78S - 79S
  • [5] RE: Estrogen Plus Progestin and Breast Cancer Incidence and Mortality in the Women's Health Initiative Observational Study
    Shapiro, Samuel
    Devilliers, Tobie J.
    Pines, Amos
    Sturdee, David W.
    Archer, David F.
    Baber, Rod J.
    Panay, Nick
    Farmer, Richard D. T.
    Stevenson, John C.
    Mueck, Alfred O.
    Burger, Henry G.
    Gompel, Anne
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2014, 106 (02):
  • [6] Evaluation of post-menopausal women receiving hormone replacement therapy before and after termination of the estrogen plus progestin trial of the Women's Health Initiative.
    Bestul, MB
    Saseen, JJ
    Hansen, L
    McCollum, M
    PHARMACOTHERAPY, 2003, 23 (10): : 1368 - 1368
  • [7] Estrogen plus progestin and cancer: The women's health initiative clinical trial.
    Smoller, S
    CHEMICAL RESEARCH IN TOXICOLOGY, 2003, 16 (12) : 1665 - 1665
  • [8] Estrogen plus progestin and cancer: The women's health initiative clinical trial.
    Smoller, S
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2003, 226 : U319 - U319
  • [9] Estrogen plus progestin (E plus P) and breast cancer incidence and mortality
    Chlebowski, Rowan T.
    Anderson, Garnet L.
    Kuller, Lewis H.
    Aragaki, Aaron K.
    Manson, JoAnn E.
    Stefanick, Marcia L.
    Johnson, Karen
    Gass, Margery
    Lane, Dorothy S.
    Ockene, Judith
    Sarto, Gloria
    Wactawski-Wende, Jean
    Rajkovic, Aleksandar
    Prentice, Ross L.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [10] Hormone therapy and venous thrombosis: Final results of the Women's Health Initiative trial of estrogen plus progestin.
    Cushman, M
    Kuller, LH
    Prentice, R
    Psaty, BM
    Sidney, S
    Stafford, R
    Rodabough, R
    Rosendaal, FR
    BLOOD, 2003, 102 (11) : 208A - 208A
12345